- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: TJ 003234 | TJ003234 | TJM2
Compound class: Antibody
Comment: Plonmarlimab (TJM2/TJ003234) is a humanized IgG1 monoclonal antibody that is designed to neutralise granulocyte-macrophage colony-stimulating factor (GM-CSF; CSF2) cytokine activity. It was developed by I-Mab Biopharma for potential to treat autoimmune diseases, and is likely to be Hu23F4-27 as claimed in I-Mab patent WO2018050111A1 .
COVID-19: Plonmarlimab is being evaluated as a mechanism to down-regulate elevated inflammation/cytokine release syndrome in patients with COVID-19  in a Phase 2/3 study.
|International Nonproprietary Names|
|TJ 003234 | TJ003234 | TJM2|
|GtoPdb PubChem SID||442878670|
|Search PubMed clinical trials||plonmarlimab|
|Search PubMed titles||plonmarlimab|
|Search PubMed titles/abstracts||plonmarlimab|